FutureWorld® is a consulting + research process for qualitatively mapping out the potential therapeutic landscape over a 5-7 year timeframe via interviews with key opinion leaders (KOLs). 

Benefits of FutureWorld®

• Understand the evolving needs in a given therapeutic area
• Explore future barriers and opportunities for new agents, diagnostics, and devices
• Provide a framework for evaluating new chemical entities in the context of new competitors and emerging scientific breakthroughs
• Obtain early insights into KOL receptivity to new therapeutic approaches that are in discovery phase
• Supplement insights from advisory boards

Information Obtainable through FutureWorld®

• Explore how KOLs anticipate a given market will change over the next 5-7 years
• Uncover KOLs’ opinions regarding underlying pathology and how future agents will address that pathology
• Discover anticipated advances in basic science, clinical practices, drug and non-drug treatment
• Define what commercial success would look like for new molecule
• Obtain preliminary inputs for clinical trial designs
• Access similarities and differences across countries (and KOL specialities)

• Strategy session to define the issues and relevant areas of exploration
• KOL identification
• B&N compiles a list of KOLs who are well respected not just in the community but also in the eyes of our clients’ scientists/ physicians, thereby enhancing buy-in and enthusiasm
• Invitees are hand-selected, providing the widest breadth of viewpoints and areas of interest
• Iterative conversations with KOLs
• Moderator’s medical/science knowledge helps guide discussion flow and promotes thoughtful follow-up questions
• Debriefs to fine-tune the conversation and introduce new issues as they emerge
• Final presentation with your prior review

Examples of FutureWorld® Projects  

• More than 25 therapeutic areas including oncology, autoimmune, musculoskeletal, neuroscience, women’s health, cardiovascular, and endocrine
• Complex conditions (SLE,  AML, SAH) as well as emerging area of opportunity (frailty, bone healing)
• Early-phase assets have included small molecules, biologics, and devices
• KOLs from around the world including North and South America, Europe, the Middle East, and  Australia

History | Mission and values | Our approach | Private Industry Services | Government Services
Global reach | Who's who | Employment opportunities | Directions | Nearby hotels | Contact us

© 2001-2010 Brintnall & Nicolini, Inc. All rights reserved.
Terms and Conditions | Privacy Statement | Safe Harbor Privacy Policy